Knight Therapeutics (GUD) Competitors C$5.74 -0.03 (-0.52%) As of 04/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock GUD vs. BHC, THCX, CRON, TLRY, ACB, FIRE, EPI, ICC, RIV, and WEEDShould you be buying Knight Therapeutics stock or one of its competitors? The main competitors of Knight Therapeutics include Bausch Health Companies (BHC), Hydropothecary (THCX), Cronos Group (CRON), Tilray Brands (TLRY), Aurora Cannabis (ACB), Supreme Cannabis (FIRE), ESSA Pharma (EPI), ICC Labs (ICC), RIV Capital (RIV), and Canopy Growth (WEED). These companies are all part of the "drug manufacturers - specialty & generic" industry. Knight Therapeutics vs. Bausch Health Companies Hydropothecary Cronos Group Tilray Brands Aurora Cannabis Supreme Cannabis ESSA Pharma ICC Labs RIV Capital Canopy Growth Bausch Health Companies (TSE:BHC) and Knight Therapeutics (TSE:GUD) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, community ranking, risk, analyst recommendations, media sentiment, earnings, valuation, profitability and institutional ownership. Which has more volatility and risk, BHC or GUD? Bausch Health Companies has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Knight Therapeutics has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Which has stronger earnings & valuation, BHC or GUD? Knight Therapeutics has lower revenue, but higher earnings than Bausch Health Companies. Knight Therapeutics is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch Health CompaniesC$6.69B0.25-C$125.65M-C$0.68-9.25Knight TherapeuticsC$348.70M1.67-C$30.73M-C$0.30-19.16 Does the media favor BHC or GUD? In the previous week, Bausch Health Companies' average media sentiment score of 0.00 equaled Knight Therapeutics'average media sentiment score. Company Overall Sentiment Bausch Health Companies Neutral Knight Therapeutics Neutral Does the MarketBeat Community favor BHC or GUD? Knight Therapeutics received 75 more outperform votes than Bausch Health Companies when rated by MarketBeat users. Likewise, 73.55% of users gave Knight Therapeutics an outperform vote while only 63.93% of users gave Bausch Health Companies an outperform vote. CompanyUnderperformOutperformBausch Health CompaniesOutperform Votes3963.93% Underperform Votes2236.07% Knight TherapeuticsOutperform Votes11473.55% Underperform Votes4126.45% Do institutionals and insiders hold more shares of BHC or GUD? 79.0% of Bausch Health Companies shares are owned by institutional investors. Comparatively, 12.6% of Knight Therapeutics shares are owned by institutional investors. 11.3% of Bausch Health Companies shares are owned by insiders. Comparatively, 45.6% of Knight Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Is BHC or GUD more profitable? Bausch Health Companies has a net margin of -1.88% compared to Knight Therapeutics' net margin of -8.81%. Bausch Health Companies' return on equity of 15.87% beat Knight Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Bausch Health Companies-1.88% 15.87% 4.16% Knight Therapeutics -8.81%-4.04%0.51% Do analysts prefer BHC or GUD? Knight Therapeutics has a consensus target price of C$7.48, suggesting a potential upside of 30.23%. Given Knight Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Knight Therapeutics is more favorable than Bausch Health Companies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch Health Companies 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Knight Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25 SummaryKnight Therapeutics beats Bausch Health Companies on 10 of the 17 factors compared between the two stocks. Remove Ads Get Knight Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GUD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GUD vs. The Competition Export to ExcelMetricKnight TherapeuticsDrug Manufacturers IndustryMedical SectorTSE ExchangeMarket CapC$580.60MC$2.15BC$5.33BC$5.47BDividend YieldN/A2.92%5.11%6.84%P/E Ratio-19.164.2821.6631.24Price / Sales1.67450.55373.39544.75Price / Cash3.8510.2538.1582.93Price / Book0.756.256.473.54Net Income-C$30.73MC$20.70BC$3.20BC$299.64M7 Day Performance1.23%1.81%2.86%2.06%1 Month Performance-4.17%-2.33%-8.56%-2.79%1 Year Performance-0.52%96.07%10.58%10.17% Knight Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GUDKnight TherapeuticsN/AC$5.74-0.5%C$7.48+30.2%-0.3%C$580.60MC$348.70M-19.16725Gap DownBHCBausch Health CompaniesN/AC$7.46-1.6%N/A-46.8%C$1.94BC$6.69B-10.9219,900Gap DownTHCXHydropothecaryN/AC$5.30+6.6%N/A+0.0%C$949.11MN/A0.00N/AHigh Trading VolumeCRONCronos Group1.1049 of 5 starsC$2.37-2.5%C$3.54+49.4%-28.7%C$625.83MC$76.86M-13.19450TLRYTilray BrandsN/AC$0.81-3.6%N/A-72.9%C$521.94MC$610.34M-1.962,650ACBAurora Cannabis1.359 of 5 starsC$5.75+0.3%C$8.75+52.2%-31.5%C$314.57MC$195.83M-7.101,073FIRESupreme CannabisN/AN/AN/AN/AC$259.40MC$53.29M-10.97400EPIESSA PharmaN/AC$8.20+7.2%N/A+0.0%C$237.87MN/A-8.2725ICCICC LabsN/AC$1.62-5.8%N/A+0.0%C$223.64MC$533,684.0095.29N/ANews CoverageGap UpRIVRIV CapitalN/AN/AN/AN/AC$213.65MC$11.33M-1.6312WEEDCanopy Growth1.4459 of 5 starsC$1.32+1.5%C$5.64+327.1%-85.3%C$212.35MC$519.68M-0.192,700 Remove Ads Related Companies and Tools Related Companies BHC Alternatives THCX Alternatives CRON Alternatives TLRY Alternatives ACB Alternatives FIRE Alternatives EPI Alternatives ICC Alternatives RIV Alternatives WEED Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:GUD) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersThe Crypto Market is About to Change LivesI've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredRadical shift coming to the stock market (read this ASAP)This is an urgent warning for all American investors … In a matter of days, we could see a radical shift in...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Knight Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
